Despite the broad availability of neuroimaging facilities such as MRI and their vast utilization to study psychiatric disorders, no neuroimaging applications have reached clinical practice in psychiatry except for excluding somatic, especially neurological disorders and quantification of atrophies in some dementias. In general, no diagnostic of predictive test for psychiatric disorders has reached clinical practice. This also includes genetic tests, which have, despite the volume of genome-wide association studies performed on patients with schizophrenia and bipolar disorder, insufficient classification performance to be useful for individual subject predictions. IMAGEMEND is targeted at the development of diagnostic and predictive tools aimed at several central issues in clinical management of mental illness and addresses an enormous public heath need. Specifically, an objective tool to discriminate schizophrenia, bipolar disorder and ADHD is especially in early disease phases are urgently required for more accurate differential diagnosis. Similarly, a neuroimaging tool to predict response and side-effect occurrence would be invaluable in clinical practice to objectify the process of treatment selection and achieve better patient outcomes through stratification at the biological level.